eli lilly glp-1 mounjaro endowment launches weight-loss drug in India, beats Novo Nordisk to major market Lilly launches GLP-1 pill, kicking

Some critics called the decision short-sighted, arguing that treating obesity now prevents far more expensive conditions later, things like heart disease, stroke, kidney failure, and certain cancers

Abstract Along the obesity pandemic, the prevalence of non-alcoholic fatty liver disease (NAFLD), often regarded as the hepatic manifestation of the metabolic syndrome, increases worldwide representing now the prevalent liver disease in western countries

In the United States, list prices for GLP-1 drugs have historically ranged between $1,000 and $1,300 per month

Improvement and competition is expected over time, whether by creating more modifications to improve half-life , improving access to the brain, converting existing injectable drugs into oral forms, combining with other agonists or antagonists (Molecules that prevent receptors/molecules from functioning) such as DPP-4 inhibitors, which help extend the half-life of peptides such as GLP-1 and GIP

According to that study , at 72 weeks participants lost up to 15% of their body weight at 5 mg, up to 20% at 10 mg, and up to 21% of body weight at the maximum weekly dose (15 mg) of Zepbound

The medicine is evolving quickly, having already expanded to include oral treatments with the first-ever FDA approval for a GLP-1 pill for weight loss for Wegovy at the end of 2025